Clinical trials: Head and Neck Cancers- Squamous Cell
Melanoma, Non-small Cell Lung Cancer
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
- Trial name
- NCT04596033
- Testing
- GEN-011, IL-2, Fludarabine
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Genocea Biosciences, Inc.
Head and Neck Cancer
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544414
- Testing
- cisplatin, docetaxel, fluorouracil
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Melanoma, Non-small Cell Lung Cancer
Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
This was a single arm, open-label, single center, cohort study to determine the efficacy and safety of AMT-116 CAR-T cells in patients with moderate or far advanced non-small cell lung carcinoma (NSCLC) and squamous cell cancer…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05117138
- Testing
- AMT-116 CAR-T cells, AMT-253 CAR-T cells
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Locally Advanced Head and Neck Squamous Cell Carcinoma
Low-Dose Weekly vs High-Dose Cisplatin
This study is a prospective open-label randomized clinical trial. Following informed consent eligible LASCCHN patients (n=100) planned for CRT will be stratified by tumor p16 status and then randomized in a 1:1 fashion to either…
- Trial name
- RADIO (NCT03649048)
- Testing
- High-Dose Cisplatin, Low-Dose Cisplatin, Radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
This is a single-center, single-arm, phase II clinical study to evaluate the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.
- Trial name
- PC-1 (NCT05993858)
- Testing
- 3cycles (Toripalimab + cetuximab), Surgery, Radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Esophageal Cancer, Gastric Cancer
Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the…
- Conditions
- Esophageal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00537121
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Cancer
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.
- Trial name
- NCT04313504
- Testing
- Niraparib, Dostarlimab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Trisha Wise-Draper
Head and Neck Cancer
Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck Cancer
Preliminary observations suggest positron emission tomography (PET) imaging with an F-18 labeled thymidine analog (FLT) can selectively identify proliferating and non-proliferating tissues, including tumors.
- Trial name
- NCT00245349
- Testing
- F-18 Fluorothymidine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Iowa
Esophageal Cancer
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
The ad-ESD trial is phase III randomized trial to compare adjuvant esophagectomy and chemoradiation for patients with clinical stage N0 and pathological stage T1b squamous cell carcinoma (after endoscopic submucosal dissection).
- Trial name
- NCT04135664
- Testing
- esophagectomy, chemoradiation, active surveillance
- Where
- 6 sites in China
- Volunteers
- 176 people
- Sponsor
- Shanghai Chest Hospital
Head and Neck Neoplasms
Prospective Evaluation of ENDOSWIR Device Versus Pathology for Squamous Cell Carcinoma of Upper Aerodigestive Tract (ENDOSWIR-VADS)
A new medical optical device named ENDOSWIR is tested to determine its ability to determine if tissues are cancer or normal tissue on ex-vivo condition for specimen of ENT squamous cell cancers.
- Trial name
- ENDOSWIR-VADS (NCT05318872)
- Testing
- ENDOSWIR
- Volunteers
- 10 people
- Sponsor
- University Hospital, Grenoble
Esophageal Squamous Cell Carcinoma
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Esophageal cancer, the 7th most common cancer globally, accounts for more than half a million deaths each year. The incidence of ESCC, the most common histologic type, has been stable, whereas the incidences of esophageal and…
- Trial name
- NCT05213312
- Testing
- Nivolumab, Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Tumours, Endometrial Cancer
A Phase 1 Study of [225Ac]-FPI-1434 Injection
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic…
- Conditions
- Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer
- Trial name
- NCT03746431
- Testing
- [111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 78 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Oral Cancer
Epstein-Barr Detection in Oral Cancer
The aim of this study is to analyze oral squamous cell carcinoma and healthy oral mucosa for the possible presence of Epstein-Barr virus (EBV).
- Trial name
- NCT01039272
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Head and Neck Squamous Cell Carcinoma
SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification
To explore the feasibility of sentinel lymph node identification by SPIO injection followed by MRI in head-and-neck cancer patients.
- Trial name
- MAG-NODE (NCT04803331)
- Testing
- SPIO-enhanced MRI
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Esophageal Cancer
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Esophageal cancer is one of the most common malignant tumors worldwide, with high invasiveness and lethality. Currently, the treatment for resectable locally advanced esophageal cancer mainly consists of a treatment model…
- Trial name
- NCT06889402
- Testing
- Neoadjuvant therapy with PD-L1 inhibitor
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Head and Neck Squamous Cell Carcinoma
Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma
Nimotuzumab (hR3) is an humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01425736
- Testing
- Chemotherapy, Nimotuzumab and Chemotherapy
- Where
- 5 sites in China
- Volunteers
- 91 people
- Sponsor
- Wei Guo
Oral Squamous Cell Carcinoma, Neoadjvant Therapy
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS>10 in the biopsy samples.
- Conditions
- Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Anti-VEGFR
- Trial name
- NCT05069857
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib (anti-VEGFR inhibitor)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Locally Advanced Head and Neck Squamous Cell Carcinoma
Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN
This study is to observe and compare the safety and tolerability of docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy and TPF induction chemotherapy combined with cisplatin…
- Trial name
- NCT03117257
- Testing
- Lobaplatin, Cisplatin
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Guiyang Medical University
Esophageal Cancer
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003864
- Testing
- carboplatin, docetaxel
- Where
- 74 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma is palliative and usually platinum based, and the patients often present with poor physical condition.
- Trial name
- NIVOTAX (NCT04282109)
- Testing
- Nivolumab + Paclitaxel, Cetuximab + Paclitaxel
- Where
- 21 sites in Spain
- Volunteers
- 141 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.